Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-07-21

FDA Approved: WEGOVY — Supplemental Application (Novo Nordisk)

View source ↗

Summary

FDA approved a supplemental application for Wegovy (semaglutide) submitted by Novo Nordisk to update its label.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • WEGOVY (Semaglutide)

Snippet

SUPPL AP for WEGOVY (SEMAGLUTIDE)